nach oben

CNS Drugs

Erschienen in:

01.10.2007 | Review Article

Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder

verfasst von: Lewis Warrington, Dr Ilise Lombardo, Antony Loebel, Kathleen Ice

Erschienen in: CNS Drugs | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Ziprasidone, a benzisothiazolyl piperazine-type atypical antipsychotic agent, has a unique receptor-binding profile. A potent antagonist of serotonin 5-HT_2A and dopamine D₂ receptors, ziprasidone has an affinity for 5-HT_2A receptors >10-fold higher than its affinity for D₂ receptors.

Ziprasidone has been shown to be effective in the treatment of bipolar disorder in patients experiencing manic or mixed episodes. It was significantly more effective than placebo in improving manic symptoms as early as day 2 of treatment in two 3-week placebo-controlled trials as monotherapy. In a 12-week, placebo-controlled trial of patients with acute mania, ziprasidone as monotherapy showed comparable efficacy with, and fewer movement-related adverse events than, haloperidol. It has demonstrated efficacy in two 1-year open-label extension trials, both as monotherapy and in combination with lithium.

Ziprasidone has a generally favourable adverse effect profile. In short-term placebo-controlled trials, there were similar discontinuation rates in active treatment and placebo recipients. While twice as many patients treated with ziprasidone compared with placebo discontinued therapy because of adverse events, the number of events was small and adverse effects were generally mild or moderate. The favourable tolerability of ziprasidone has been confirmed in long-term extension studies and its use was not associated with weight gain or dyslipidaemia. Ziprasidone-related movement disorders occurred infrequently.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351: 476–86PubMedCrossRef

American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1–50CrossRef

Goldberg JF, Garno JL, Portera L, et al. Qualitative differences in manic symptoms during mixed versus pure mania. Compr Psychiatry 2000; 41: 237–41PubMedCrossRef

Keller MB, Lavori PW, Coryell W, et al. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis 1993; 181: 238–45PubMedCrossRef

McElroy SL, Keck Jr PE, Pope Jr HG, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992; 149: 1633–44PubMed

Dilsaver SC, Chen YW, Swann AC, et al. Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994; 151: 1312–5PubMed

Goldberg JF, Garno JL, Leon AC, et al. Association of recurrent suicidal ideation with nonremission from acute mixed mania. Am J Psychiatry 1998; 155: 1753–5PubMed

Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741–8PubMedCrossRef

10.

Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651–8PubMedCrossRef

11.

Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841–9PubMedCrossRef

12.

Pope Jr HG, Lipinski Jr JF. Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of “schizophrenic” symptoms in the light of current research. Arch Gen Psychiatry 1978; 35: 811–28PubMedCrossRef

13.

Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990

14.

McElroy SL, Keck Jr PE, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996; 57 Suppl. 3: 14–26

15.

Potkin SG, Keck Jr PE, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 301–10PubMedCrossRef

16.

Ramey TS, Giller EL, English P, et al. Ziprasidone efficacy and safety in acute bipolar mania: 21-week study [abstract]. 158th Annual Meeting of the American Psychiatric Association; 2005 May 14–19; Atlanta (GA)

17.

Weisler R, Warrington L, Dunn J, et al. Adjunctive ziprasidone in bipolar mania: short- and long-term data [poster]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York (NY)

18.

Geodon prescribing information (revised March 2007) [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_geodon.pdf [Accessed 2007 Apr 25]

19.

Data on file. Pfizer Inc.

20.

Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002; 36: 839–51PubMedCrossRef

21.

Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001; 62 Suppl. 7: 4–10

22.

Schmidt AW, Lebel LA, Howard Jr HR, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425: 197–201PubMedCrossRef

23.

Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13PubMed

24.

Tatsumi M, Jansen K, Blakely RD, et al. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999 Mar 5; 368(2–3): 277–83PubMedCrossRef

25.

Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of switching medications. J Clin Psychiatry 2007; 68 Suppl. 6: 14–23

26.

Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000; 49 Suppl. 1: 5–13S

27.

Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49 Suppl. 1: 15–20S

28.

Daniel DG, Copeland LF. Ziprasidone: a comprehensive review and clinical use of a novel antipsychotic. Exp Opin Invest Drugs 2000; 9: 819–28CrossRef

29.

Prakash C, Kamel A, Gummerus J, et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone. Drug Metab Dist 1997; 25: 863–72

30.

Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 1998; 18: 9–15PubMed

31.

Wilner KD, Demattos SB, Anziano RJ, et al. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol 2000; 49 Suppl. 1: 43–7S

32.

FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox® capsules (ziprasidone HCl) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf [Accessed 2007 Jul 18]

33.

Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003; 23: 229–32PubMed

34.

Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 Suppl. 1: 35–42S

35.

Aweeka F, Jayesekara D, Horton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000; 49 Suppl. 1: 27–33S

36.

Everson G, Lasseter KC, Anderson KE, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol 2000; 49 Suppl. 1: 21–26S

37.

Miceli JJ, Anziano RJ, Robarge L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000; 49 Suppl. 1: 65–70S

38.

Miceli JJ, Smith M, Robarge L, et al. The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000; 49 Suppl. 1: 71–6S

39.

Wilner KD, Hansen RA, Folger CJ, et al. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000; 49 Suppl. 1: 57–60S

40.

Keck Jr PE, Potkin SG, Giller E, et al. Ziprasidone’s long-term efficacy and safety in bipolar disorder [poster]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York (NY)

41.

Potkin SG, Sprague R, Keck Jr PE, et al. Ziprasidone in bipolar mania: efficacy across patient subgroups [poster]. 156th Annual Meeting of the American Psychiatric Association; 2004 May 1–6; New York (NY)

42.

Stahl S, Lombardo I, Loebel A, et al. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies [poster]. Annual Meeting of the American College of Neuropsychiatry; 2005 Dec 3–6; Honolulu (HI)

43.

Warrington L, Potkin SG, Ice K, et al. Ziprasidone’s long-term efficacy in subpopulations with bipolar mania [poster]. 157th Annual Meeting of the American Psychiatric Association; 2005 May 21–26; Atlanta (GA)

44.

Gianfrancesco FD, Rajagopalan K, Sajatovic M, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 2006; 67: 222–32PubMedCrossRef

45.

Fleurence RL, Dixon JM, Revicki DA. Economics of atypical antipsychotics in bipolar disorder: a review of the literature. CNS Drugs 2006; 20(7): 591–9PubMedCrossRef

46.

Warrington L, Dunn J, Mandel R. Ziprasidone safety and tolerability in bipolar mania: review of trial data [poster]. 157th Annual Meeting of the American Psychiatric Association; 2005 May 21–26; Atlanta (GA)

47.

Lombardo I, Rappard F, Mandel F. Ziprasidone does not exacerbate mania or worsen depression during treatment of bipolar mania: an analysis of pooled clinical trial data. Eur Psychiatry 2007; 22: S254CrossRef

48.

Ballas C, Yang C, O’Reardon J, et al. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004; 4: 179–86PubMedCrossRef

49.

Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psych 2003; 64: 580–8CrossRef

50.

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601CrossRef

51.

Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96PubMed

52.

Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65Suppl. 7: S4–18

53.

Gianfrancesco F, White R, Wang R-H, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003; 23: 328–35PubMedCrossRef

54.

Lean MEJ, Pajonk FG. Patients on atypical antipsychotics: another high-risk group for type 2 diabetes. Diabetes Care 2003; 26: 1597–605PubMedCrossRef

55.

Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337–45PubMedCrossRef

56.

Avella J, Wetli CV, Wilson JC, et al. Fatal olanzapine-induced hyperglycaemic ketoacidosis. Am J Forensic Med Pathol 2004; 25: 172–5PubMedCrossRef

57.

Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. Epub 2007 Jul 18

58.

Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 1837–47PubMedCrossRef

59.

Versiani M. Ziprasidone in bipolar disorder. Expert Opin Pharmacother 2006 Jun; 7(9): 1221–8PubMedCrossRef

60.

McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005; 66 Suppl. 3: 26–36

61.

Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med 2005; 353: 1209–23PubMedCrossRef

62.

Moller HJ. Antipsychotic and antidepressant effects of second generation antipsychotics: two different pharmacologic mechanisms? Eur Arch Psychiatry Clin Neurosci 2005; 255: 190–201PubMedCrossRef

63.

Meier A, Neumann AC, Jordan W, et al. Ziprasidone decreases cortisol excretion in healthy subjects. Br J Clin Pharmacol 2005; 60: 330–6PubMedCrossRef

64.

ClinicalTrials.gov [online]: Available from URL: http://clinicaltrials.gov/ct/search;jsessionid=6717F8A2D14220B69B340104B1BD64D3?term=ziprasidone…submit=Search [Accessed 2007 Aug 14]

Titel: Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder
verfasst von: Lewis Warrington
Dr Ilise Lombardo
Antony Loebel
Kathleen Ice
Publikationsdatum: 01.10.2007
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 10/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200721100-00004

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2007

Biological Treatments for Amfetamine Dependence

Mechanisms Underlying Postoperative Nausea and Vomiting and Neurotransmitter Receptor Antagonist-Based Pharmacotherapy

The Role of Anti-Inflammatory Agents in Parkinson’s Disease

Hashimoto’s Encephalopathy